- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05057793
Efficacy Study for Geko Device in VLU Patients (Canada)
A Prospective, Multicentre, Randomised, Assessor Blinded Study Comparing the Efficacy, Including Participant Reported Outcomes, of Daily Geko™ Therapy in Conjunction With Standard Care to Standard Care Alone, in Patients With Venous Leg Ulcers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is designed to evaluate the efficacy of geko™ therapy for 12 hours daily in conjunction with Standard Care (SC), consisting of multilayer, multicomponent compression therapy intended for the treatment of VLUs, compared to SC alone in participants with VLUs.
The study will be a multicentre study with study centres in Ontario Canada.
The study will have three phases:
- A four-week Run-In Phase (day 0-28)
- A four-week Treatment Phase (day 28-56)
- A long term Follow-Up Phase (day 84, 112 & 140 after EOT)
During the Run-In Phase all participants will receive SC only and will be evaluated on a weekly basis (day 0, 7, 14 & 21). On day 28, once the Investigator has confirmed the participant's continued eligibility, randomization and assignment to study treatment will take place. During the long term follow-up phase, participants continue with their assigned study treatment and will be seen and evaluated on day 84, 112 and 140
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hamilton, Canada, ONL8R2R3
- The Mayer Institute
-
Oakville, Canada, ONL6M4J2
- Vascular Health Bronte
-
Waterloo, Canada, ONN2L6H7
- Care Partners (Waterloo)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged ≥ 18 years, able to provide written informed consent and comply with all study procedures and visit schedule
- Intact healthy skin at the site of geko™ device application.
- Have a (chronic) venous leg ulcer determined to be due to underlying venous disease following evaluation in a multi-professional setting or by a vascular surgeon, specialist physician or nurse wound specialist in accordance with Wounds Canada (2018), Health Quality Ontario Standards
- A VLU of approximately ≥ 5cm2 and ≤ 40cm2 at study enrolment i.e. Run in Phase Visit 1. If more than one ulcer is present, the largest ulcer within the given size range will be designated the study ulcer and the only one included in the study. If other ulcerations are present on the same leg, they must be more than 2 cm apart if they are two separate wounds.
- Study ulcer (current episode of ulceration in case of ulcer recurrence) has been present for at least 6 weeks but no more than 5 years prior to study entry.
- Ankle-Brachial Pressure Index (ABPI) of 0.8 -1.2 ± 0.05 inclusive (or equivalent measure) measured at study entry or within 12 weeks of study entry.
- No active local index wound infection for a minimum of 48 hours prior to study entry (RV1)
- No systemic antimicrobial treatment for a minimum of seven days prior to study entry (RV1) prescribed for index wound infection
- Must understand and is willing and able to participate in the study and to comply with all study procedures and study visit schedule
Exclusion Criteria:
- Known allergy or intolerance to any of the protocol-stipulated treatments
- History of significant haematological disorders (e.g. Sickle Cell disease)
- History of Deep Vein Thrombosis (DVT) within six months preceding study entry
- History of Pyoderma Gangrenosum or other inflammatory ulceration
- BMI ≥ 40
- Pregnancy or risk of pregnancy
- Use of investigational drug or device within four weeks prior to study entry that may interfere with the study
- Use of any neuro-modulation device
- Surgery during three months prior to study entry (such as abdominal, gynaecological, hip or knee replacement)
- Trauma to the lower limbs that would prevent geko™ from stimulating the common peroneal nerve.
- Implanted with a pacemaker or implantable cardioverter defibrillator (ICD).
- Any medication deemed by the Investigator to potentially interfere with the study treatment (e.g. higher dose systemic steroids).
- Participation in any other clinical study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard of care
Multilayer, multicomponent compression intended for the treatment of VLU
|
|
Active Comparator: Standard of care + geko 12h
Multilayer multicomponent compression intended for the treatment of VLU in conjuction with geko™ therapy 12 hours daily
|
The geko device will be self-administered and deliver 12 hours of therapy daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in linear healing rate in the treatment phase compared to the run-in phase
Time Frame: 8 weeks
|
The pair-wise comparison of linear healing rate (wound margin advance, WMA) during Treatment Phase compared with WMA from the Run-in Phase both the treatment arm (SC plus 12 hours daily treatment with the geko™ W device or variant) and control arm (SC only).
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weekly change in linear healing rate
Time Frame: 8 weeks
|
Weekly wound margin advance of the study ulcer measured by an independent blinded wound expert using digital images taken at each weekly visit until end of treatment.
|
8 weeks
|
Change in pain score using the VAS (Visual Analogue Scale)
Time Frame: 8 weeks
|
Patient will indicate their pain score at each weekly visit using a visual analogue scale (VAS), with 0 being no pain at all and 100 being worst pain imaginable (measured in mm)
|
8 weeks
|
Change in quality of life using the EQ-5D-5L (health-related quality of life measure) questionnaire
Time Frame: 8 weeks
|
EQ-5D-5L a descriptive system for health-related quality of life (HRQoL) states in adults, consisting of five dimensions (mobility, self-care, usual activities, pain & discomfort, anxiety & depression).
Participant will complete questionnaire at the beginning of the run in phase, at randomization and at the end of treatment.
Each level is scored ona 5 level severity ranking, with 1 being no problems, to 5 being extreme problems.
|
8 weeks
|
Change in quality of life using the CWIS (Cardiff Wound Impact Schedule)
Time Frame: 8 weeks
|
Cardiff Wound Impact Schedule (CWIS) is used to measure the impact of chronic wounds (leg ulcers and diabetic foot ulcers) on HRQoL and identify areas of participant concern.
The questionnaire will be completed by the participant at the beginning of the run in phase, at randomization and at the end of treatment.
The overall score will be between 0 and 100, with a higher score indicating a better quality of life.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Garry Sibbald, University of Toronto
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FSK-VLU-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leg Ulcer
-
Nantes University HospitalCompletedHypertensive Leg UlcerFrance
-
University Hospital, Strasbourg, FranceTerminated
-
Assistance Publique - Hôpitaux de ParisCompletedMARTORELL'S ULCER | Hypertensive Leg Ulcer | Necrotic AngiodermatitisFrance
-
Pharma 2100WithdrawnArterial Leg UlcerDenmark
-
SoftOx Solutions ASCompletedVenous Leg Ulcer | Chronic Leg UlcerDenmark
-
Piomic Medical AGVenenklinik Bellevue; Kantonsspital Nidwalden; Spital MännedorfCompletedLeg Ulcers Venous | Leg Ulcer Arterial | Leg Ulcer MixedSwitzerland
-
Ahram Canadian UniversityRecruiting
-
SolasCure LimitedCompletedVenous Leg Ulcer | Leg Injuries and DisordersUnited States, Hungary, United Kingdom
-
EmoledRecruiting
-
Imperial College LondonImperial College Healthcare NHS TrustRecruiting
Clinical Trials on geko
-
Queen Mary University of LondonCompletedDeep Vein ThrombosisUnited Kingdom
-
Firstkind LtdNational Institute for Health Research, United Kingdom; University of California and other collaboratorsRecruitingDeep Vein Thrombosis | Venous Thromboembolism | Stroke, Acute | Pulmonary EmbolismUnited Kingdom
-
Firstkind LtdRecruitingEdema | SurgerySpain, United States, United Kingdom
-
Firstkind LtdActive, not recruitingDiabetic Foot Ulcer | Venous Leg Ulcer | Wound | Arterial Leg UlcerUnited Kingdom, United States
-
Firstkind LtdCompletedStroke | Wound Heal | Cardiac Pacemaker Electrical Interference | Edema LegUnited Kingdom
-
Lawson Health Research InstituteCompletedEdema | Kidney Transplant | Kidney Pancreas TransplantCanada
-
University College, LondonCompletedMultiple Sclerosis | Overactive BladderUnited Kingdom
-
Lawson Health Research InstituteWithdrawn
-
University Hospital Southampton NHS Foundation...CompletedDeep Vein ThrombosisUnited Kingdom